Our partners at the Advanced Research Projects Agency for Health (ARPA-H) recently announced a new funding opportunity through the Ocular Laboratory for Analysis of Biomarkers (OCULAB) program. OCULAB seeks to develop a tear-based biomarker measurement system that can be inserted into the tear duct for continuous health monitoring and provide ultra-precise medication dosing for personalized treatment via a closed-loop delivery system.
“What if your eyes were a window to your health? The OCULAB platform has the potential to make continuous monitoring a reality for both ocular and systemic diseases, allowing for more precise interventions in ophthalmological, hormone, inflammatory, and other disorders,” said ARPA-H Director Renee Wegrzyn, Ph.D.
Massachusetts is home to ARPA-H’s Investor Catalyst Hub. Massachusetts-based organizations can join the Hub’s nationwide network of spokes collectively working to speed the commercialization of groundbreaking health solutions.
